Excessive Hair Growth in a Patient with Psoriatic Erythroderma Following Secukinumab Administration

An 85-year-old man with psoriatic erythroderma and androgenetic alopecia-like hair loss experienced significant hair regrowth on his scalp after being treated with secukinumab, an anti-IL-17A antibody. His skin condition improved within one month, and hair growth was observed two months into the treatment, continuing at the six-month mark. The document proposes that the hair growth could be due to either the alleviation of scalp inflammation from psoriasis or a direct effect of IL-17A on alopecia pathogenesis. Additionally, an increase in black hair was noted, suggesting IL-17A might also influence hair pigmentation. This case highlights the potential of anti-IL-17A therapy in treating hair loss and altering hair pigmentation.